Literature DB >> 11163696

An experimental study on triclabendazole resistance of Fasciola hepatica in sheep.

C P Gaasenbeek1, L Moll, J B Cornelissen, P Vellema, F H Borgsteede.   

Abstract

The efficacy of triclabendazole in sheep experimentally infected with Fasciola hepatica was studied. Two groups of 12 lambs were infected with a susceptible (S) or a resistant (R) strain of F. hepatica. Eight weeks after infection, six lambs of each group (ST and RT) were treated with triclabendazole (10mg/kg). The other lambs were used as untreated controls (SC and RC). The parameters studied were: GLDH, gamma-GT, ELISA measuring antibodies against recombinant cathepsin-L(1) and eggs per gram faeces (epg). The lambs were slaughtered 16 weeks after infection and the number of flukes counted. The GLDH, gamma-GT levels and the OD value of the ELISA decreased as a result of the treatment in group ST. Patent infections were observed in all animals of groups SC, RT and RC. In group ST, occasionally a few eggs were found in five lambs. The percentage of flukes was 31.3 in SC and 37.6 in RC. In the treated groups ST and RT, the percentage of flukes was 0.06 and 33.6, respectively. These results corresponded to efficacies of 99.8% in the susceptible and 10.8% in the resistant strain. Since the resistant strain was isolated from a mixed cattle and sheep farm, it confirms the presence of triclabendazole resistance in the Netherlands.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163696     DOI: 10.1016/s0304-4017(00)00413-1

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  16 in total

1.  Efficacy of an experimental fasciolicide against immature and mature Fasciola hepatica in artificially infected calves.

Authors:  Y Vera Montenegro; F Ibarra Velarde; E Liébano Hernández; H Quiroz Romero; R Castillo Bocanegra; A Hernández Campos; P Ochoa Galván
Journal:  Parasitol Res       Date:  2003-12-03       Impact factor: 2.289

2.  Immature triclabendazole-resistant Fasciola hepatica: tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha.

Authors:  M McConville; G P Brennan; M McCoy; R Castillo; A Hernandez-Campos; F Ibarra; I Fairweather
Journal:  Parasitol Res       Date:  2006-10-03       Impact factor: 2.289

3.  A deep exploration of the transcriptome and "excretory/secretory" proteome of adult Fascioloides magna.

Authors:  Cinzia Cantacessi; Jason Mulvenna; Neil D Young; Martin Kasny; Petr Horak; Ammar Aziz; Andreas Hofmann; Alex Loukas; Robin B Gasser
Journal:  Mol Cell Proteomics       Date:  2012-08-16       Impact factor: 5.911

4.  Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro.

Authors:  S M Walker; B McKinstry; J C Boray; G P Brennan; A Trudgett; E M Hoey; H Fletcher; I Fairweather
Journal:  Parasitol Res       Date:  2004-10-28       Impact factor: 2.289

5.  Purification, characterization, and immunolocalization of paramyosin from the adult stage of Fasciola hepatica.

Authors:  Martín Cancela; Carlos Carmona; Silvina Rossi; Blas Frangione; Fernando Goñi; Patricia Berasain
Journal:  Parasitol Res       Date:  2004-02-12       Impact factor: 2.289

6.  Genetic heterogeneity of Fasciola hepatica isolates in the northwest of Spain.

Authors:  M P Vara-Del Río; H Villa; M Martinez-Valladares; F A Rojo-Vázquez
Journal:  Parasitol Res       Date:  2007-05-27       Impact factor: 2.289

7.  Albendazole enantiomeric metabolism and binding to cytosolic proteins in the liver fluke Fasciola hepatica.

Authors:  H Solana; S Scarcella; G Virkel; C Ceriani; J Rodríguez; C Lanusse
Journal:  Vet Res Commun       Date:  2008-08-26       Impact factor: 2.459

8.  Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands.

Authors:  Annemarie J S Winkelhagen; Theo Mank; Peter J de Vries; Robin Soetekouw
Journal:  Emerg Infect Dis       Date:  2012-06       Impact factor: 6.883

9.  Fascioliasis and intestinal parasitoses affecting schoolchildren in Atlixco, Puebla State, Mexico: epidemiology and treatment with nitazoxanide.

Authors:  José Lino Zumaquero-Ríos; Jorge Sarracent-Pérez; Raúl Rojas-García; Lázara Rojas-Rivero; Yaneth Martínez-Tovilla; María Adela Valero; Santiago Mas-Coma
Journal:  PLoS Negl Trop Dis       Date:  2013-11-21

10.  Confirmation of Fasciola hepatica resistant to triclabendazole in naturally infected Australian beef and dairy cattle.

Authors:  Yvette M Brockwell; Timothy P Elliott; Glenn R Anderson; Rex Stanton; Terry W Spithill; Nicholas C Sangster
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2013-12-11       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.